오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

substance pty ltd - salix alba, quantity: 240 mg (equivalent: salix alba, qty 6 g; equivalent: salicin, qty 60 mg); terminalia chebula, quantity: 200 mg (equivalent: chebulinic and chebulagic acid, qty 40 mg; equivalent: terminalia chebula, qty 1000 mg); curcuma longa, quantity: 25 mg (equivalent: curcuminoids (of curcuma longa), qty 11.15 mg; equivalent: curcuma longa, qty 500 mg); zingiber officinale, quantity: 50 mg (equivalent: gingerols calculated as gingerol-[6], qty 5 mg; equivalent: zingiber officinale, qty 500 mg) - capsule, hard - excipient ingredients: microcrystalline cellulose; magnesium stearate; hypromellose; silicon dioxide; betadex; polysorbate 80 - traditionally used in ayurvedic medicine to body tonic ; traditionally used in western herbal medicine to anti-inflammatory/relieve inflammation ; traditionally used in ayurvedic medicine to anti-inflammatory/relieve inflammation ; traditionally used in ayurvedic medicine to analgesic/anodyne/relieve pain ; traditionally used in ayurvedic medicine to decrease/reduce/relieve mild joint aches and pains ; traditionally used in western herbal medicine to decrease/reduce/relieve mild joint aches and pains ; traditionally used in ayurvedic medicine to decrease/reduce/relieve symptoms of mild arthritis/mild osteoarthritis ; traditionally used in ayurvedic medicine to decrease/reduce/relieve mild joint inflammation/swelling ; traditionally used in western herbal medicine to decrease/reduce/relieve muscle pain/ache/soreness ; traditionally used in western herbal medicine to decrease/reduce/relieve headache symptoms ; traditionally used in ayurvedic medicine to decrease/reduce/relieve menstruation pain/dysmenorrhoea

싱가포르 - 영어 - HSA (Health Sciences Authority)

novartis (singapore) pte ltd - fingolimod hcl 0.28mg eqv fingolimod - capsule - fingolimod hcl 0.28mg eqv fingolimod 0.25mg

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

wockhardt bio pty ltd - voriconazole, quantity: 200 mg - injection, powder for - excipient ingredients: sodium chloride; hydroxypropylbetadex - voriwok is indicated for treatment of the following fungal infections:,invasive aspergillosis.,serious candida infections (including c. krusei), including systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia).,serious fungal infections caused by scedosporium spp and fusarium spp.,other serious fungal infections, in patients intolerant of, or refractory to, other therapy.,prophylaxis in patients who are at high risk of developing invasive fungal infections. the indication is based on studies including patients undergoing haematopoietic stem cell transplantation.

영국 - 영어 - MHRA (Medicines & Healthcare Products Regulatory Agency)

morningside healthcare ltd - metformin hydrochloride - modified-release tablet - 500mg

영국 - 영어 - MHRA (Medicines & Healthcare Products Regulatory Agency)

morningside healthcare ltd - metformin hydrochloride - modified-release tablet - 1gram

영국 - 영어 - MHRA (Medicines & Healthcare Products Regulatory Agency)

actavis uk ltd - metformin hydrochloride - modified-release tablet - 1gram

영국 - 영어 - MHRA (Medicines & Healthcare Products Regulatory Agency)

actavis uk ltd - metformin hydrochloride - modified-release tablet - 500mg

아르메니아 - 영어 - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

morningside pharmaceuticals ltd - metformin (metformin hydrochloride) - tablets prolonged-release - 500mg

아르메니아 - 영어 - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

morningside pharmaceuticals ltd - metformin (metformin hydrochloride) - tablets prolonged-release - 1000mg

아르메니아 - 영어 - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

morningside pharmaceuticals ltd - metformin (metformin hydrochloride) - tablets prolonged-release - 500mg